Cargando…

P-162: Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study

Detalles Bibliográficos
Autores principales:	Tan, Joanne, Wellard, Cameron, Moore, Elizabeth, Spencer, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403072/ http://dx.doi.org/10.1016/S2152-2650(22)00492-X

Ejemplares similares

The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
por: Lim, Kenneth JC, et al.
Publicado: (2023)

P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
por: McQuilten, Zoe, et al.
Publicado: (2022)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

Real World Multiple Myeloma Registry from Jordan, a Developing Country
por: Qasem, Farah, et al.
Publicado: (2022)

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
por: Blimark, Cecilie Hveding, et al.
Publicado: (2018)

P-160: Disparities in multiple myeloma between hispanics and non-hispanics – real world outcomes
por: Shaikh, Hira, et al.
Publicado: (2022)

P916: COEXISTENCE OF ≥2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP
por: Katodritou, E., et al.
Publicado: (2022)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013
por: Remes, Kari, et al.
Publicado: (2018)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
por: Kastritis, Efstathios, et al.
Publicado: (2017)

AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario
por: Farswan, Akanksha, et al.
Publicado: (2021)

P817: VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2-ISS) IN A LARGE POPULATION-BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.
por: Katodritou, Eirini, et al.
Publicado: (2023)

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries
por: Chen, Tianhui, et al.
Publicado: (2016)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

The Danish National Multiple Myeloma Registry
por: Gimsing, Peter, et al.
Publicado: (2016)

Validation of the Revised Myeloma Comorbidity Index and other comorbidity scores in a multicenter German study group multiple myeloma trial
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Comment on: AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario
por: Khalil, Rania M., et al.
Publicado: (2021)

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
por: Tandon, N, et al.
Publicado: (2017)

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
por: Engelhardt, Monika, et al.
Publicado: (2017)

An imaging review of extramedullary myeloma
por: Kay, M, et al.
Publicado: (2015)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK
por: Keil, F., et al.
Publicado: (2022)

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
por: Campioni, M., et al.
Publicado: (2019)

P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISEASES REGISTRIES (MRDR)
por: Chai, K. L., et al.
Publicado: (2022)

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry
por: Bergin, Krystal, et al.
Publicado: (2016)

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
por: Radocha, Jakub, et al.
Publicado: (2018)

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
por: Hulin, Cyrille, et al.
Publicado: (2018)

Real-world renal function among patients with multiple myeloma in the United States
por: Mikhael, Joseph, et al.
Publicado: (2021)

PB2698: MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY-PROMPT-2 TRIAL
por: Moore, Elizabeth, et al.
Publicado: (2023)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study
por: Wang, Yu-tong, et al.
Publicado: (2023)

Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)
por: Zhong, Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kf2jd583k5o3e6f9f89nliif2b